Top Markets
Coin of the day
Crossject Société Anonyme Crossject Société Anonyme

Crossject Société Anonyme

ALCJ
Classement en actions #12697
Crossject Société Anonyme develops needle-free injection systems. The company... Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Prix de l'action
$2.04
Capitalisation boursière
$122.58M
Changement (1 jour)
4.48%
Changement (1 an)
-1.05%
Pays
FR
Échange Crossject Société Anonyme (ALCJ)

Catégorie

Ratio P/B pour Crossject Société Anonyme (ALCJ)
Ratio P/B au July 2026 TTM : -19.13
Selon les derniers rapports financiers et le cours de l'action de Crossject Société Anonyme, le ratio cours/valeur comptable actuel (TTM) est -19.13. À la fin de 2023, le ratio P/B était de -34.70.
Historique du ratio P/B pour Crossject Société Anonyme de 2010 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) -19.13 -49.09%
2024 -37.58 8.29%
2023 -34.70 -158.98%
2022 58.83 -594.78%
2021 -11.89 -81.50%
2020 -64.28 -524.02%
2019 15.16 54.90%
2018 9.79 46.48%
2017 6.68 29.69%
2016 5.15 -33.97%
2015 7.80 105.46%
2014 3.80 -92.39%
2013 49.91 -339.62%
2012 -20.83 12.72%
2011 -18.48 290.65%
2010 -4.73 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
8.0767 -142.21%
US
1.954 -110.21%
FR
5.8147 -130.39%
DE
8.564 -144.76%
JP
1.7598 -109.20%
US